AKT is a therapeutic target in myeloproliferative neoplasms

The majority of patients with BCR-ABL1-negative myeloproliferative neoplasms (MPN) harbor mutations in JAK2 or MPL, which lead to constitutive activation of the JAK/STAT, PI3K, and ERK signaling pathways. JAK inhibitors by themselves are inadequate in producing selective clonal suppression in MPN an...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Irum, Huang, Zan, Wen, Qiang, Stankiewicz, Monika J., Gilles, Laure, Goldenson, Benjamin, Schultz, Rachael, Diebold, Lauren, Gurbuxani, Sandeep, Finke, Christy M., Lasho, Terra L., Koppikar, Priya, Pardanani, Animesh, Stein, Brady, Altman, Jessica K., Levine, Ross L., Tefferi, Ayalew, Crispino, John D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023863/
https://www.ncbi.nlm.nih.gov/pubmed/23748344
http://dx.doi.org/10.1038/leu.2013.167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4023863/
https://www.ncbi.nlm.nih.gov/pubmed/23748344
http://dx.doi.org/10.1038/leu.2013.167

Ejemplares similares